EINDHOVEN, The Netherlands, August 4 /PRNewswire/ -- With today’s final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) medical research, making CTMM one of the largest public-private partnerships in the world. This pivotal point in the organisation’s development firmly positions the Netherlands as one of the world’s leading destinations for translational biomedical research.
“The 15 million euro allocated to this prostate cancer project, which brings the total allocated CTMM funding to 265 million euro, should enable the project team to make a real difference to the diagnosis and treatment of a disease that counts among the biggest killers of men,” said Peter Luijten, CTMM Chief Scientific Officer.
With this final project approval, CTMM has fulfilled the initial objectives of its business plan by establishing public-private research consortia to address the world’s most prevalent diseases. The CTMM project portfolio now comprises 18 projects conducting translational molecular medicine research into innovative new techniques for the diagnosis and treatment of cancer, cardiovascular, neurodegenerative and infectious/auto-immune disease. In total, more than 100 partners from industry and academia are involved in the projects, which are funded on the basis of 25% from industry, 25% from academia and 50% from the Dutch government.
About CTMM
CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalised treatment for oncology, cardiovascular, neurodegenerative and infectious/auto-immune disease - the four main areas of disease causing mortality and diminished quality of life in the western world. CTMM operates by inviting, assessing and funding multidisciplinary projects that involve active participation by Netherlands-based academia and industry. All CTMM projects are judged by an independent International Scientific Advisory Committee and approved by a Supervisory Board based on their significant potential to translate research knowledge into clinical practice. CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%). For more information, visit http://www.ctmm.nl
For specific information on the projects visit http://www.ctmm.nl
SOURCE CTMM
CONTACT: For further information contact Eric Caldenhoven, Program Manager
Oncology, Tel: +31(0)40-8002305 or eric.caldenhoven@ctmm.nl.
